Matching articles for "bumetanide"
Issue 1752 · April 13, 2026 Free
In Brief: A Bumetanide Nasal Spray (Enbumyst) for Edema

Enbumyst (Corstasis), a nasal spray formulation of the loop diuretic bumetanide, has been approved by the FDA for (short-term) treatment of edema associated with congestive heart failure, renal disease…

Med Lett Drugs Ther. 2026 Apr 13; 68(1752):62-3 doi:10.58347/tml.2026.1752d
Enbumyst (Corstasis), a nasal spray formulation of the loop diuretic bumetanide, has been approved by the FDA for (short-term) treatment of edema associated with congestive heart failure, renal disease (including nephrotic syndrome), or hepatic disease in adults. It is the first diuretic nasal spray formulation to become available in the US. Bumetanide has been available for years in oral and IV formulations.
Issue 1750 · March 16, 2026 Free
In Brief: A Second Subcutaneous Furosemide Infusor (Lasix ONYU) for Heart Failure

The FDA has approved Lasix ONYU (SQ Innovation), a subcutaneous formulation of the loop diuretic furosemide administered via a wearable pump (onbody infusor), for treatment of edema in adults with chronic…

Med Lett Drugs Ther. 2026 Mar 16; 68(1750):47-8 doi:10.58347/tml.2026.1750d
The FDA has approved Lasix ONYU (SQ Innovation), a subcutaneous formulation of the loop diuretic furosemide administered via a wearable pump (onbody infusor), for treatment of edema in adults with chronic heart failure (HF). A similar product, Furoscix , is approved for treatment of edema in chronic HF or chronic kidney disease. Furosemide has been available for years in oral and IV formulations for such use.
Issue 1729 · May 26, 2025
Drugs for Chronic Heart Failure

Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF…

Med Lett Drugs Ther. 2025 May 26; 67(1729):81-8 doi:10.58347/tml.2025.1729a
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Patients with an LVEF of 41-49% have heart failure with mildly reduced or mid-range ejection fraction.
Issue 1729 · May 26, 2025 Free
Comparison Chart: Some Drugs for HFrEF

View the Comparison Chart: Some Drugs for HFrEF

Med Lett Drugs Ther. 2025 May 26; 67(1729):e1-15 doi:10.58347/tml.2025.1729b
View the Comparison Chart: Some Drugs for HFrEF
Issue 1709 · August 19, 2024 Free
In Brief: A New Torsemide Formulation (Soaanz) for Edema (online only)

The FDA has approved Soaanz (Sarfez), a new formulation of the loop diuretic torsemide, for treatment of edema associated with heart failure or renal disease in adults. Torsemide has been available generically…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):e141 doi:10.58347/tml.2024.1709h
The FDA has approved Soaanz (Sarfez), a new formulation of the loop diuretic torsemide, for treatment of edema associated with heart failure or renal disease in adults. Torsemide has been available generically for years for treatment of hypertension and treatment of edema due to heart failure, renal disease, or hepatic disease. According to the manufacturer, Soaanz tablets are formulated to provide a gradual and sustained diuresis, lowering the risk of excessive urination and hypokalemia.
Issue 1703 · May 27, 2024
Drugs for Hypertension

American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed…

Med Lett Drugs Ther. 2024 May 27; 66(1703):81-8 doi:10.58347/tml.2024.1703a
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1668 · January 23, 2023 Free
In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure

The FDA has approved Furoscix (scPharmaceuticals), a subcutaneous formulation of the loop diuretic furosemide administered via a single-use, on-body infusor, for treatment of congestion due to fluid overload…

Med Lett Drugs Ther. 2023 Jan 23; 65(1668):14-5 doi:10.58347/tml.2023.1668d
The FDA has approved Furoscix (scPharmaceuticals), a subcutaneous formulation of the loop diuretic furosemide administered via a single-use, on-body infusor, for treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II-III chronic heart failure (HF). Furosemide ( Lasix , and generics) has been available for years in oral and IV formulations.
Issue 1626 · June 14, 2021
Drugs for Chronic Heart Failure

Among patients with chronic heart failure, those with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≥50%…

Med Lett Drugs Ther. 2021 Jun 14; 63(1626):89-96
Among patients with chronic heart failure, those with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Those with a LVEF of 41-49% are an intermediate group more similar to patients with HFpEF.
Issue 1619 · March 8, 2021
Comparison Table: Some Drugs for HFrEF (online only)

View the Comparison Table: Some Drugs for HFrEF

Med Lett Drugs Ther. 2021 Mar 8; 63(1619):e1-14
View the Comparison Table: Some Drugs for HFrEF
Issue 1598 · May 18, 2020
Drugs for Hypertension

Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2020 May 18; 62(1598):73-80
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1569 · April 8, 2019
Drugs for Chronic Heart Failure

Patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≤50% and symptoms of heart failure are…

Med Lett Drugs Ther. 2019 Apr 8; 61(1569):49-54
Patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≤50% and symptoms of heart failure are considered to have heart failure with preserved ejection fraction (HFpEF). There is little evidence that drug treatment improves clinical outcomes in patients with HFpEF.
Issue 1569 · April 8, 2019
Expanded Table: Some Drugs for HFrEF (online only)

View the Expanded Table: Some Drugs for HFrEF

Med Lett Drugs Ther. 2019 Apr 8; 61(1569):e57-62
View the Expanded Table: Some Drugs for HFrEF
Issue 1516 · March 13, 2017
Drugs for Hypertension

in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2017 Mar 13; 59(1516):41-8
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1474 · August 3, 2015
Sacubitril/Valsartan (Entresto) for Heart Failure

The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular death…

Med Lett Drugs Ther. 2015 Aug 3; 57(1474):107-9
The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular death and heart failure hospitalization in patients with heart failure with reduced ejection fraction. Sacubitril is the first neprilysin inhibitor to become available in the US.
Issue 1460 · January 19, 2015
Drugs for Chronic Heart Failure

Heart failure is usually associated with left ventricular dysfunction. According to recent guidelines, patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with…

Med Lett Drugs Ther. 2015 Jan 19; 57(1460):9-13
Heart failure is usually associated with left ventricular dysfunction. According to recent guidelines, patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) or systolic heart failure. Patients with a LVEF ≥50% and symptoms of heart failure are considered to have heart failure with preserved ejection fraction (HFpEF) or diastolic heart failure; there is little evidence that drug treatment improves clinical outcomes in these patients. The treatment of acute heart failure is not included here.
Issue 121 · September 1, 2012
Drugs for Chronic Heart Failure

Chronic systolic heart failure is usually associated with a left ventricular ejection fraction (LVEF) of ≤40%. Many patients with symptoms of heart failure have higher ejection fractions, but there is no…

Treat Guidel Med Lett. 2012 Sep; 10(121):69-72
Chronic systolic heart failure is usually associated with a left ventricular ejection fraction (LVEF) of ≤40%. Many patients with symptoms of heart failure have higher ejection fractions, but there is no evidence that drug treatment of heart failure with preserved systolic function (LVEF >40%) improves clinical outcomes. Some of the drugs commonly used now for treatment of chronic heart failure are listed in the table on page 71.
Issue 113 · January 1, 2012
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for…

Treat Guidel Med Lett. 2012 Jan; 10(113):1-10
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed previously.
Issue 83 · July 1, 2009
Drugs for Treatment of Chronic Heart Failure

The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such…

Treat Guidel Med Lett. 2009 Jul; 7(83):53-6
The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such as cardiac resynchronization, implanted cardiac defibrillators (ICDs), ventricular assist devices and ultrafiltration for the relief of congestion will not be reviewed here.
Issue 77 · January 1, 2009
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs…

Treat Guidel Med Lett. 2009 Jan; 7(77):1-10
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines ( volume 1, page 19, December 2002 ) and in The Medical Letter ( volume 50, page 73, September 22, 2008 ).
Issue 41 · January 1, 2006
Drugs for Treatment of Heart Failure

The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the…

Treat Guidel Med Lett. 2006 Jan; 4(41):1-4
The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the incidence of sudden death in patients with heart failure and the treatment of decompensated heart failure were discussed in previous issues.
Issue 34 · June 1, 2005
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs…

Treat Guidel Med Lett. 2005 Jun; 3(34):39-48
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs for treatment of hypertensive emergencies are not discussed here.
Issue 8 · April 1, 2003
Drugs for Treatment of Heart Failure

The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well…

Treat Guidel Med Lett. 2003 Apr; 1(8):53-6
The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as hemodynamic mechanisms. The treatment of decompensated heart failure is not discussed here; drugs used for this indication were reviewed in Cardiovascular Drugs in the ICU, Treatment Guidelines from The Medical Letter 2002; 1:19 .
Issue 6 · February 1, 2003
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs…

Treat Guidel Med Lett. 2003 Feb; 1(6):33-40
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.
Issue 1099 · March 5, 2001
Drugs for Hypertension

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 2001 Mar 5; 43(1099):17-22
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Issue 1048 · March 12, 1999
Drugs for Hypertension

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 1999 Mar 12; 41(1048):23-8
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Issue 1045 · January 29, 1999
Drugs for Chronic Heart Failure

The choice of drugs for treatment of heart failure depends on both hemodynamic and neurohormonal factors.

Med Lett Drugs Ther. 1999 Jan 29; 41(1045):12-4
The choice of drugs for treatment of heart failure depends on both hemodynamic and neurohormonal factors.
Issue 985 · October 11, 1996
Drugs for Chronic Heart Failure

Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on…

Med Lett Drugs Ther. 1996 Oct 11; 38(985):92-4
Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on different mechanisms are commonly used together.
Issue 929 · August 19, 1994
Torsemide (Demadex) - A New Loop Diuretic

Torsemide, a new loop diuretic similar in action to bumetanide (Bumex) and furosemide, was recently approved by the US Food and Drug Administration for treatment of edema due to congestive heart failure, renal…

Med Lett Drugs Ther. 1994 Aug 19; 36(929):73-4
Torsemide, a new loop diuretic similar in action to bumetanide (Bumex) and furosemide, was recently approved by the US Food and Drug Administration for treatment of edema due to congestive heart failure, renal disease, or hepatic disease and also for treatment of hypertension. It is available for both oral and intravenous use.
Issue 896 · May 14, 1993
Drugs for Chronic Heart Failure

Chronic heart failure results from an iterplay between hemodynamic and neurohormonal factors (M Packer, Lancet, 340:88, 92, 1992). For patients with heart failure due to left ventricular dysfunction, drugs…

Med Lett Drugs Ther. 1993 May 14; 35(896):40-2
Chronic heart failure results from an iterplay between hemodynamic and neurohormonal factors (M Packer, Lancet, 340:88, 92, 1992). For patients with heart failure due to left ventricular dysfunction, drugs that decrease cardicac preload and afterload and those that increase contractility are commonly used together.
Issue 805 · November 17, 1989
Is Indapamide (Lozol) Safer Than A Thiazide?

Recent advertisements for indapamide ( Lozol - Rorer), an oral antihypertensive/diuretic (Medical Letter, 26:17, 1984), claim that the drug, unlike thiazide diuretics, does not significantly increase serum…

Med Lett Drugs Ther. 1989 Nov 17; 31(805):103
Recent advertisements for indapamide ( Lozol - Rorer), an oral antihypertensive/diuretic (Medical Letter, 26:17, 1984), claim that the drug, unlike thiazide diuretics, does not significantly increase serum cholesterol and has a minimal impact on potassium. Indapamide has no thiazide ring but, like chlorthalidone ( Hygroton ; and others) and hydrochlorothiazide ( HydroDiuril ; and others), it does have a sulfamoyl benzamide moiety, which is probably responsible for its natriuretic and diuretic effects. Unlike the thiazides, it also has a methylindoline moiety, which apparently decreases peripheral resistance.